Please login to the form below

Not currently logged in
Email:
Password:

chronic kidney disease

This page shows the latest chronic kidney disease news and features for those working in and with pharma, biotech and healthcare.

AZ finally gets EU nod for Veltassa rival Lokelma

AZ finally gets EU nod for Veltassa rival Lokelma

The risk of hyperkalaemia increases significantly for patients with chronic kidney disease (CKD) and for those who take certain heart failure (HF) medicines that increase potassium levels in the blood.

Latest news

  • J&J seeks US OK to add CV claim to Invokana label J&J seeks US OK to add CV claim to Invokana label

    Adults with type 2 diabetes are four times more likely to develop cardiovascular disease, and this is the leading cause of death in these patients. ... chronic kidney disease patients both with and without diabetes.

  • Vifor wins European approval for Veltassa Vifor wins European approval for Veltassa

    In the EU, Veltassa is indicated to treat adults with hyperkalaemia, including those who develop the disease as a side effect while being treated with renin angiotensin aldosterone system (RAAS) inhibitor ... therapy due to heart failure and/or chronic

  • Pfizer gets FDA panel recommendation for biosimilar EPO Pfizer gets FDA panel recommendation for biosimilar EPO

    Pfizer is seeking approval for its biosimilar for the treatment anaemia caused by chronic kidney disease (CKD), HIV drug zidovudine and cancer chemotherapy, as well as to reduce the need for

  • FDA turns down AZ's ZS-9 once again on manufacturing issues FDA turns down AZ's ZS-9 once again on manufacturing issues

    Elevated serum potassium is associated with multiple diseases - including chronic heart failure (CHF) and chronic kidney disease (CKD) - and can lead to potentially fatal abnormal heart rhythms.

  • NICE set to back Parsabiv for kidney disease complication NICE set to back Parsabiv for kidney disease complication

    NICE set to back Parsabiv for kidney disease complication. Draft guidance recommends Amgen treatment for secondary hyperparathyroidism. ... The first new treatment in a decade for a common complication of chronic kidney disease has been given a green

More from news
Approximately 2 fully matching, plus 82 partially matching documents found.

Latest Intelligence

  • The invisible army The invisible army

    Studies with COPD and chronic kidney disease patients indicate that carers can have a positive influence on patient adherence to medication and healthy behaviours, thus driving positive outcomes in the process.

  • Deal Watch December 2016 Deal Watch December 2016

    1, 000. Akebia (US). Otsuka (Japan). Licence (US). Vadadustat: oral hypoxia-inducible factor (HIF) stabiliser in phase III for anaemia of chronic kidney disease. ... The Scandinavian company, Nuevolution, uses its drug discovery platform Chemetics to

  • Deal Watch February 2016 Deal Watch February 2016

    Nestlé has stated it wants to build a significant business from its Health Science unit focusing on food-related products for the treatment of chronic diseases. ... licence. 105. †† Genexine/ Shanghai Chemo WanBang Biopharma. GX-E2 (EPO-hyFc), a

  • Deal Watch December 2015 Deal Watch December 2015

    575. Crealta. Horizon. Acquisition - company. Krystexxa marketed for treatment of chronic refractory gout. ... 397. Akebia (US). Mitsubishi. Collaboration, licence. Vadadustat for treatment of anaemia in chronic kidney disease.

  • Pharma deals during March 2014 Pharma deals during March 2014

    Turning east again, AZ has also recently announced a research collaboration with Shenzhen University Health Science Center for preclinical research focused on chronic kidney disease (CKD). ... Kidney disease in China is a significant and growing problem.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
StratX

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics